Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autoantigen-loaded Polymeric Microparticles associate with B cells and promote tolerogenic antigen presentation in a mouse model of experimental autoimmune encephalomyelitis.

Nature communications·2026

Same author

Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8<sup>+</sup> T cell fate.

Research square·2026

Same author

High-avidity cathepsin-G-specific CAR-T cells for the treatment of acute myeloid leukemia.

Blood·2026

Same author

NG2-targeting macrophages inhibit 3D invasion of patient-derived glioblastoma spheroids.

bioRxiv : the preprint server for biology·2026

Same author

Publisher Correction: Atlas-guided discovery of transcription factors for T cell programming.

Nature·2026

Same author

The dynamic myeloid-enriched microenvironment of glioblastoma: a major challenge to immunotherapy efficacy.

Frontiers in immunology·2026

Search research articles

Related Experiment Video

Updated: Dec 29, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.

Giovanni Fucà^1,2, Loic Reppel³, Elisa Landoni³

¹Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. gdotti@med.unc.edu ivanilic@email.unc.edu.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|February 5, 2020

Summary

Chimeric antigen receptor (CAR) T-cell therapy shows promise for solid tumors but faces challenges. This review explores strategies to improve CAR T-cell specificity and overcome tumor microenvironment barriers for better cancer treatment outcomes.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Production of Human CRISPR-Engineered CAR-T Cells

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

Related Experiment Videos

Last Updated: Dec 29, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Production of Human CRISPR-Engineered CAR-T Cells

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

Area of Science:

Immunotherapy
Oncology
Biotechnology

Background:

CAR T-cell therapy has revolutionized hematologic cancer treatment.
Significant challenges remain for CAR T-cell efficacy in solid tumors, including on-target, off-tumor effects and tumor complexity.

Purpose of the Study:

To review recent strategies addressing therapeutic impediments for CAR T-cell therapy in solid tumors.
To highlight advancements in antigen targeting, tumor specificity, and overcoming the tumor microenvironment.

Main Methods:

Review of recent scientific literature and clinical attempts.
Focus on strategies for improved antigen targeting and overcoming physical and immunological barriers.

Main Results:

Anecdotal objective responses observed in solid tumors.
Key challenges include on-target, off-tumor activity and the complex solid tumor biology.
Promising strategies involve enhanced antigen targeting and overcoming tumor barriers.

Conclusions:

CAR T-cell therapy for solid tumors requires overcoming significant hurdles.
Strategies to improve tumor specificity, address heterogeneity, and navigate the tumor microenvironment are crucial for therapeutic success.